COMPPARE Newsletter: Fall/Winter 2021-22

connection


Dr. Nancy P. Mendenhall

A Message from Dr. Nancy Mendenhall

Our focus on IMRT enrollment has increased as we have become more aware of practice pattern changes that have impacted IMRT accrual, specifically the increased utilization of ultra-hypofractionated radiation (stereotactic body radiation therapy, or SBRT). Read Dr. Mendenhall’s message.

 


MDACC

Partner Site Spotlight: The University of Texas MD Anderson Cancer Center

Founded in Houston, TX, in 1941, the University of Texas MD Anderson Cancer Center has a distinguished history and is currently one of only 51 National Cancer Institute-designated comprehensive cancer centers – follow the conversation here.


From Principles to Practice: Building Partnerships for Trust and Equity in Health Research with COMPPAREFrom Principles to Practice: Trust & Equity in Health Research

COMPPARE participated in a special panel discussion during PCORI’s 7th annual meeting entitled “From Principles to Practice: Building Partnerships for Trust and Equity in Health Research” – read about this successful presentation.


CaPTC Biennial MeetingThe Science of Survivorship

Dr. Nancy Mendenhall was invited to speak at the sixth annual Biennial Science of Global Prostate Cancer Disparities in Black Men Conference, held virtually November 10-13, 2021 – learn more.

 


COMPPARE Reaches Its Pragmatic Proton GoalCOMPPARE Reaches Its Pragmatic Proton Enrollment Goal

The COMPPARE Coordinating Center announced on September 1, 2021 that the study had reached its Pragmatic Proton enrollment goal of 900 patients, completing and closing that arm of the proton cohort – get the scoop on this success.

 


Pat GreanyThe Patient’s Perspective: Remembering Pat Greany

Pat was a fountain of knowledge on the prevention, diagnosis, and treatment of prostate cancer. His technical education/training and his inquiring mind made him a sponge for all things prostate cancer-related. Read how Pat made a difference in the lives of patients.

 


TheranosticsA Look at the New Technology Known as Theranostics

In theranostics, a special diagnostic molecule is first used to find the cancer. That same molecule is then modified and used to go back in and destroy the cancer – learn more about it.

 


Enrollment 10-16-20COMPPARE Study Progress

Want the latest information on COMPPARE? Find out how many patients have enrolled and how many sites are currently enrolling patients on the COMPPARE Study Progress page.

 


Research reported in this newsletter was partially funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (PCS-2017C1-0422). The views, statements, and opinions presented in this newsletter are solely the responsibility of the authors and do not necessarily represent the views of PCORI, its Board of Governors, or Methodology Committee.


Archive

We look forward to sharing our patient-centric news with you. Below you can find an archive of our issues and subscribe to receive COMPPARE Connection in your inbox.

 


COMPPARE Newsletter Subscription

Contact the COMPPARE Team